Monopar Therapeutics (MNPR) Current Assets (2016 - 2020)
Historic Current Assets for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $18.1 million.
- Monopar Therapeutics' Current Assets rose 25405.29% to $18.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.1 million, marking a year-over-year increase of 25405.29%. This contributed to the annual value of $13.2 million for FY2019, which is 8242.18% up from last year.
- According to the latest figures from Q3 2020, Monopar Therapeutics' Current Assets is $18.1 million, which was up 25405.29% from $12.7 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Current Assets registered a high of $18.1 million during Q3 2020, and its lowest value of $2.1 million during Q4 2016.
- Its 5-year average for Current Assets is $8.9 million, with a median of $7.9 million in 2018.
- Its Current Assets has fluctuated over the past 5 years, first surged by 33582.25% in 2017, then crashed by 3523.37% in 2019.
- Monopar Therapeutics' Current Assets (Quarter) stood at $2.1 million in 2016, then surged by 335.82% to $9.1 million in 2017, then dropped by 20.58% to $7.3 million in 2018, then surged by 82.42% to $13.2 million in 2019, then skyrocketed by 36.72% to $18.1 million in 2020.
- Its last three reported values are $18.1 million in Q3 2020, $12.7 million for Q2 2020, and $12.7 million during Q1 2020.